Personalis(PSNL) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Personalis Reports Second Quarter 2025 Financial Results Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume FREMONT, Calif. – August 5, 2025 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its "Win-in-MRD" strategy: Second Quarter 2025 and Recent Business Highlights "The results of our "Win-in-MRD" strategy are clear, with an impr ...